In 2023, Keenova Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Keenova Therapeutics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 |
|---|---|---|
Total Scope 1 | 89,052a | 89,551a |
Total Scope 2 | ||
Market-Based | 74,164a | N/A |
Location-Based | 73,947a | 82,347a |
Total Scope 3 | N/A | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Keenova Therapeutics amounted to 162,999 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Keenova Therapeutics decreased by 5.18%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2023, the total Scope 1 emissions of Keenova Therapeutics were 89,052 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2022), Keenova Therapeutics's Scope 1 emissions remained relatively stable, indicating that Keenova Therapeutics's emissions have plateaued with no significant change in its operational footprint.a
In 2023, Keenova Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 74,164 tCO₂e using the market-based method and 73,947 tCO₂e using the location-based method.a
Compared to the previous year (2022), Keenova Therapeutics's Scope 2 emissions (Location-Based) fell by 10.2% in 2023, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2023, Keenova Therapeutics reported its Scope 2 emissions using the market-based method and using the location-based method.a